Serum levels of soluble B and T lymphocyte attenuator predict overall survival in patients undergoing immune checkpoint inhibitor therapy for solid malignancies
Open Access
- 22 April 2021
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 149 (5) , 1189-1198
Abstract
Therapy with immune checkpoint inhibitors (ICIs) can lead to durable tumor control in patients with various advanced stage malignancies. However, this is not the case for all patients, leading to an ongoing search for biomarkers predicting response and outcome to ICI. The B and T lymphocyte attenuator (BTLA) is an immune checkpoint expressed on immune cells that was shown to modulate therapeutic responses. Here, we evaluate circulating levels of its soluble form, soluble B and T lymphocyte attenuator (sBTLA), as a biomarker for the prediction of treatment response and outcome to ICI therapy. Serum levels of sBTLA were analyzed by multiplex immunoassay in n = 84 patients receiving ICI therapy for solid malignancies and 32 healthy controls. BTLA expression was evaluated on peripheral blood mononuclear cells in a subset of patients (n = 6) using multicolor flow cytometry. Baseline sBTLA serum levels were significantly higher in cancer patients compared to healthy controls. Importantly, circulating sBTLA levels were an independent prognostic factor for overall survival (OS). As such, patients with initial sBTLA levels above the calculated prognostic cutoff value (311.64 pg/mL) had a median OS of only 138 days compared to 526 for patients with sBTLA levels below this value (P = .001). Uni‐ and multivariate Cox regression analyses confirmed the prognostic role of sBTLA in the context of ICI therapy. Finally, we observed a significant correlation between sBTLA levels and the frequency of CD3 + CD8 + BTLA+ T cells in peripheral blood. Thus, our data suggest that circulating sBTLA could represent a noninvasive biomarker to predict outcome to ICI therapy, helping to select eligible therapy candidates.Keywords
Funding Information
- Deutsche Krebshilfe (110043)
- H2020 European Research Council (771083)
This publication has 38 references indexed in Scilit:
- Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trialThe Lancet Oncology, 2016
- Pembrolizumab versus Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2015
- Durable Responses With PD-1 Inhibition in Lung and Kidney Cancer and the Ongoing Search for Predictive BiomarkersJournal of Clinical Oncology, 2015
- Pembrolizumab for the Treatment of Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Interfering with coinhibitory molecules: BTLA/HVEM as new targets to enhance anti-tumor immunityImmunology Letters, 2013
- BTLA as a biomarker and mediator of sepsis-induced immunosuppressionCritical Care, 2013
- Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff OptimizationPLOS ONE, 2012
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Balancing co-stimulation and inhibition with BTLA and HVEMNature Reviews Immunology, 2006
- VACUTAINER® CPT™ and Ficoll density gradient separation perform equivalently in maintaining the quality and function of PBMC from HIV seropositive blood samplesBMC Immunology, 2006